MRTX(Delisted)
Mirati TherapeuticsยทNASDAQ
--
--(--)
MRTX fundamentals
Mirati Therapeutics (MRTX) released its earnings on Mar 8, 2018: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Mar 8, 2018
EPS
Revenue
Revenue & Expenses
MRTX has released its 2023 Q3 earnings report, with revenue of 16.40M, reflecting a YoY change of 201.97%, and net profit of -161.90M, showing a YoY change of 6.72%. The Sankey diagram below clearly presents MRTX's revenue sources and cost distribution.
Key Indicators
Mirati Therapeutics (MRTX) key financial stats and ratios, covering profitability, financial health, and leverage.
Mirati Therapeutics (MRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Mirati Therapeutics (MRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Mirati Therapeutics (MRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Mirati Therapeutics (MRTX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Mirati Therapeutics (MRTX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
